Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 14, 2018
Feb 9, 2018
CAS Group Supports Improved DealCompany Currently has Sufficient Votes to Approve Merger ATLANTA, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that the reconvened Special Meeting of Stockholders has been further adjourned to 10:00 AM, EST on February 13, 2018 in order to provide the Company's st...
Feb 9, 2018
Feb 7, 2018
ATLANTA and SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) and Vaxart, Inc. today announced that the companies have agreed to amend the terms of their previously announced merger agreement to increase the proposed ownership percentage of Aviragen stockholders of the combined company. Under...
Feb 6, 2018
ATLANTA, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that its Special Meeting of Stockholders, scheduled for and convened on February 6, 2018, has been adjourned to provide the Company's stockholders additional time to consider and vote FOR Aviragen's proposed merger with Vaxart, Inc. Aviragen inten...
Jan 31, 2018
Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA, Jan. 31, 2018 (GLOBE NEWSWIRE) --  Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued the following statement urging stockholders to vot...
Jan 31, 2018
Jan 31, 2018
Jan 26, 2018
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed Merger with Vaxart ATLANTA, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued the follo...
Jan 24, 2018
Reiterates Benefits of Proposed Merger with Vaxart Illustration 1 ...
Jan 11, 2018
Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ATLANTA, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today reiterated its support of the pending merger with Va...
Nov 29, 2017
ATLANTA, Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the completion of patient enrollment in its Phase 2 CT4 clinical trial evaluating teslexivir (BTA074) for th...
Nov 2, 2017
ATLANTA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months ended September 30, 2017. "Earlier this week we were pleased to announce the culmination of our strategic review process with the signing of a definitive merger agreement with Vaxart, which we believ...
Oct 30, 2017
Merged Company to Focus on Development of Antiviral Vaccines and Therapeutics Based on Proprietary Delivery Technology Platform Conference Call to be Held Today at 8:30 AM ET  ATLANTA and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and develo...
Oct 30, 2017
Page:
...
Next Last
 
= add release to Briefcase